Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

Peter E. Clark; Philippe E. Spiess; Neeraj Agarwal; Rick Bangs; Stephen A. Boorjian; Mark K. Buyyounouski; Jason A. Efstathiou; Thomas W. Flaig; Terence Friedlander; Richard E. Greenberg; Khurshid A. Guru; Noah Hahn; Harry W. Herr; Christopher Hoimes; Brant A. Inman; A. Karim Kader; Adam S. Kibel; Timothy M. Kuzel; Subodh M. Lele; Joshua J. Meeks; Jeff Michalski; Jeffrey S. Montgomery; Lance C. Pagliaro; Sumanta K. Pal; Anthony Patterson; Daniel Petrylak; Elizabeth R. Plimack; Kamal S. Pohar; Michael P. Porter; Wade J. Sexton; Arlene O. Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A. Dwyer; Courtney Smith

doi:10.6004/jnccn.2016.0131

Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. MeeksJeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, Courtney Smith

Research output: Contribution to journal › Article › peer-review

93 Scopus citations

Abstract

These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

Original language	English
Pages (from-to)	1213-1224
Number of pages	12
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	14
Issue number	10
DOIs	https://doi.org/10.6004/jnccn.2016.0131
State	Published - Oct 1 2016

Keywords

Antineoplastic Agents/therapeutic use
Humans
Urinary Bladder Neoplasms/drug therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2016.0131

Cite this

Clark, P. E., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Efstathiou, J. A., Flaig, T. W., Friedlander, T., Greenberg, R. E., Guru, K. A., Hahn, N., Herr, H. W., Hoimes, C., Inman, B. A., Kader, A. K., Kibel, A. S., Kuzel, T. M., Lele, S. M., ... Smith, C. (2016). Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 14(10), 1213-1224. https://doi.org/10.6004/jnccn.2016.0131

@article{eb9db140a6cc4b06be2c71213f123d61,

title = "Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines",

abstract = "These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Gu{\'e}rin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.",

keywords = "Antineoplastic Agents/therapeutic use, Humans, Urinary Bladder Neoplasms/drug therapy",

author = "Clark, {Peter E.} and Spiess, {Philippe E.} and Neeraj Agarwal and Rick Bangs and Boorjian, {Stephen A.} and Buyyounouski, {Mark K.} and Efstathiou, {Jason A.} and Flaig, {Thomas W.} and Terence Friedlander and Greenberg, {Richard E.} and Guru, {Khurshid A.} and Noah Hahn and Herr, {Harry W.} and Christopher Hoimes and Inman, {Brant A.} and Kader, {A. Karim} and Kibel, {Adam S.} and Kuzel, {Timothy M.} and Lele, {Subodh M.} and Meeks, {Joshua J.} and Jeff Michalski and Montgomery, {Jeffrey S.} and Pagliaro, {Lance C.} and Pal, {Sumanta K.} and Anthony Patterson and Daniel Petrylak and Plimack, {Elizabeth R.} and Pohar, {Kamal S.} and Porter, {Michael P.} and Sexton, {Wade J.} and Siefker-Radtke, {Arlene O.} and Guru Sonpavde and Jonathan Tward and Geoffrey Wile and Dwyer, {Mary A.} and Courtney Smith",

year = "2016",

month = oct,

day = "1",

doi = "10.6004/jnccn.2016.0131",

language = "English",

volume = "14",

pages = "1213--1224",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "10",

}

Clark, PE, Spiess, PE, Agarwal, N, Bangs, R, Boorjian, SA, Buyyounouski, MK, Efstathiou, JA, Flaig, TW, Friedlander, T, Greenberg, RE, Guru, KA, Hahn, N, Herr, HW, Hoimes, C, Inman, BA, Kader, AK, Kibel, AS, Kuzel, TM, Lele, SM, Meeks, JJ, Michalski, J, Montgomery, JS, Pagliaro, LC, Pal, SK, Patterson, A, Petrylak, D, Plimack, ER, Pohar, KS, Porter, MP, Sexton, WJ, Siefker-Radtke, AO, Sonpavde, G, Tward, J, Wile, G, Dwyer, MA & Smith, C 2016, 'Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 14, no. 10, pp. 1213-1224. https://doi.org/10.6004/jnccn.2016.0131

TY - JOUR

T1 - Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

AU - Clark, Peter E.

AU - Spiess, Philippe E.

AU - Agarwal, Neeraj

AU - Bangs, Rick

AU - Boorjian, Stephen A.

AU - Buyyounouski, Mark K.

AU - Efstathiou, Jason A.

AU - Flaig, Thomas W.

AU - Friedlander, Terence

AU - Greenberg, Richard E.

AU - Guru, Khurshid A.

AU - Hahn, Noah

AU - Herr, Harry W.

AU - Hoimes, Christopher

AU - Inman, Brant A.

AU - Kader, A. Karim

AU - Kibel, Adam S.

AU - Kuzel, Timothy M.

AU - Lele, Subodh M.

AU - Meeks, Joshua J.

AU - Michalski, Jeff

AU - Montgomery, Jeffrey S.

AU - Pagliaro, Lance C.

AU - Pal, Sumanta K.

AU - Patterson, Anthony

AU - Petrylak, Daniel

AU - Plimack, Elizabeth R.

AU - Pohar, Kamal S.

AU - Porter, Michael P.

AU - Sexton, Wade J.

AU - Siefker-Radtke, Arlene O.

AU - Sonpavde, Guru

AU - Tward, Jonathan

AU - Wile, Geoffrey

AU - Dwyer, Mary A.

AU - Smith, Courtney

PY - 2016/10/1

Y1 - 2016/10/1

N2 - These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

AB - These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

KW - Antineoplastic Agents/therapeutic use

KW - Humans

KW - Urinary Bladder Neoplasms/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=84990174465&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000385057100003&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2016.0131

DO - 10.6004/jnccn.2016.0131

M3 - Article

C2 - 27697976

SN - 1540-1405

VL - 14

SP - 1213

EP - 1224

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 10

ER -

Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this